

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1(Currently amended). A conjugate of (1) at least one therapeutic agent for joint diseases which is bonded via a spacer to [[and]] (2) hyaluronic acid, a hyaluronic acid derivative or a salt thereof, wherein ~~said at least one therapeutic agent for joint diseases covalently binds to~~ a carboxyl group of said hyaluronic acid, ~~the hyaluronic acid~~ or derivative or [[the]] salt thereof and an amino group of said spacer form an amide bond via a spacer.

Claim 2 (Cancelled).


3(Previously presented). The conjugate of claim 1, wherein the therapeutic agent for joint diseases is a matrix metalloprotease inhibitor.

Claim 4 (Cancelled).

5(Previously presented). The conjugate of claim 3, wherein the weight ratio of the matrix metalloprotease inhibitor to the entire conjugate is 0.01 to 50%.

6(Previously presented). The conjugate of claim 3, wherein the matrix metalloprotease inhibitor is a hydroxamic acid residue.

7(Previously presented). The conjugate of claim 3, wherein the matrix metalloprotease inhibitor is a hydroxamic acid residue represented by the general formula (1):



wherein


R<sub>1</sub> is a hydrogen atom, a hydroxyl group or a straight-chain or branched-chain alkyl group having 1 to 8 carbon atoms;

R<sub>2</sub> is a straight-chain or branched-chain alkyl group having 1 to 8 carbon atoms;

R<sub>3</sub> is a straight chain or branched alkyl group having 1 to 8 carbon atoms which may be substituted with a cycloalkyl group, an aryl group or a heterocyclic group; and

R<sub>4</sub> is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms.

8(Previously presented). The conjugate of claim 1, wherein the spacer is represented by the general formula (2):



(2)

wherein


$R_5$  is a straight-chain or branched-chain alkylene group having 1 to 8 carbon atoms;

$R_6$  is an oxygen atom or a methylene or imino group which may be substituted with a straight-chain or branched-chain alkyl group having 1 to 4 carbon atoms;

$R_7$  is a straight-chain or branched-chain alkylene group having 1 to 10 carbon atoms into which one to three oxygen atoms may be inserted; and

$R_8$  is an oxygen atom, a sulfur atom or  $NR_9$ , wherein  $R_9$  is a hydrogen atom or a straight-chain or branched-chain alkyl group having 1 to 4 carbon atoms.

9(Previously presented). The conjugate of claim 3, wherein the matrix metalloprotease inhibitor and the spacer constitute a moiety represented by the general formula (3):



(3)

wherein

$R_{12}$  is a straight-chain or branched-chain alkylene group having 2 to 23 carbon atoms into which one imino group and/or one to four oxygen atoms may be inserted; and

$R_{13}$  is a hydrogen atom or a straight-chain or branched-chain alkyl group having 1 to 4 carbon atoms.

10 (Previously presented). The conjugate of claim 3, wherein the matrix metalloprotease inhibitor in the form of a conjugate with hyaluronic acid, a hyaluronic acid derivative or a salt thereof inhibits a matrix metalloprotease *in situ*.

11 (Currently amended). A method for preparing the conjugate of claim 1 comprising binding a site of the therapeutic agent for joint diseases that does not affect the activity of the agent to a carboxyl group, ~~a hydroxyl group or a functional group at the reducing end~~ of hyaluronic acid, a hyaluronic acid derivative or a salt thereof ~~by direct chemical reaction or~~ via a spacer.

12 (Previously presented). A pharmaceutical composition comprising the conjugate of any one of claims 1, 3, 5-10, 18, 19, 23 and 24 and a pharmaceutically acceptable diluent.

Claims 13-16 (Cancelled).

17(Previously presented). A method for treating a patient having a joint disease comprising administering a pharmaceutical composition containing a pharmaceutically effective amount of the conjugate of any one of claims 1, 3, 5-10, 18, 19, 23 and 24 as the effective ingredient to the patient.

18(Previously presented). The conjugate of claim 1, wherein the therapeutic agent for joint diseases is selected from the group consisting of a cyclooxygenase 2 inhibitor, an antirheumatic agent and a matrix metalloprotease inhibitor.

Claims 19-21 (Cancelled).

22(Previously presented). A method of treating a joint disease in a patient in need thereof, comprising administering a pharmaceutical composition to said patient in an amount sufficient for said treatment, wherein said pharmaceutical composition comprises a conjugate in accordance with claim 1.

23(Previously presented). The conjugate of claim 1, wherein component (1) is a single therapeutic agent for joint disease.

24(Previously presented). The conjugate of claim 1, wherein component (2) is hyaluronic acid or a salt thereof.

25(Previously presented). The method of claim 17, wherein the joint disease is selected from the group consisting

Appln. No. 09/700,879

Amd. dated November 1, 2004

Reply to Office Action of October 15, 2004

of osteoarthritis, rheumatoid arthritis, and scapulohumeral  
periarthrititis.